Stock events for BiomX, Inc. (PHGE)
In January 2026, BiomX issued a statement regarding recent common stock trading activity. In December 2025, the company announced a $3.0 million private placement and the discontinuation of its Phase 2b BX004 trial following an internal review. In November 2025, an update was provided on the BX004 Phase 2b trial in Cystic Fibrosis, and BiomX Inc. announced a 1-for-19 reverse stock split. The company's share price experienced a significant decline of 64.63% between February 27, 2025, and February 26, 2026.
Demand Seasonality affecting BiomX, Inc.’s stock price
As a clinical-stage biopharmaceutical company, BiomX, Inc. does not have commercialized products, and its revenue primarily stems from grant funding and collaborations rather than product sales. Therefore, traditional demand seasonality for products and services is not applicable to BiomX, Inc. at this stage.
Overview of BiomX, Inc.’s business
BiomX, Inc. is a clinical-stage microbiome company focused on developing natural and engineered phage therapies to target and destroy harmful bacteria associated with chronic diseases. The company operates within the Healthcare sector and the Biotechnology industry, utilizing its proprietary BOLT platform to discover, validate, and customize phage compositions against specific bacterial targets. Its major product candidates in development include BX004 for chronic pulmonary infections in cystic fibrosis patients, BX011 targeting Staphylococcus aureus infections associated with diabetic foot infections, and BX211 for the treatment of diabetic foot osteomyelitis associated with S. aureus. Previously, the company's pipeline also included BX001 for improving the appearance of acne-prone skin, BX002 for eradicating bacterial targets associated with inflammatory bowel disease, and BX003 for specific strains of Klebsiella pneumoniae.
PHGE’s Geographic footprint
BiomX, Inc. is headquartered in Ness Ziona, Israel, and is incorporated in Delaware, United States. Its primary activities involve research and development and clinical trials.
PHGE Corporate Image Assessment
BiomX's brand reputation has been influenced by its clinical development progress and financial activities. The discontinuation of the Phase 2b BX004 trial in December 2025 could be perceived negatively. The company also issued a statement in January 2026 concerning recent common stock trading activity. Analyst sentiment is mixed, with some analysts maintaining a "Buy" recommendation and a median price target suggesting significant upside, while an AI-powered analysis gives a "Strong Sell" rating due to factors like upcoming earnings and high volatility.
Ownership
As of March 2026, BiomX Inc. has 17 institutional owners and shareholders holding a total of 302,117 shares, representing 40.57% of BiomX's stock. Major institutional owners include Deerfield Management Company, L.p., Nantahala Capital Management, LLC, and others. Individual investors account for 6.9% of the ownership based on the 1000 largest holdings, and the company's leadership holds an 18.81% direct ownership stake.
